Search
Etidocaine
go.drugbank.com/drugs/DB08987ApprovedIt is an injectable local anesthetic during surgery, labor, and delivery. Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.
Oditrasertib
go.drugbank.com/drugs/DB21526InvestigationalOditrasertib is under investigation in clinical trial NCT05630547 (A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis … The usage of the INN stem '-sertib' in the name indicates that Oditrasertib is a serine/threonine kinase inhibitor.
Eliapixant
go.drugbank.com/drugs/DB21465InvestigationalEliapixant is under investigation in clinical trial NCT04614246 (Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive … The usage of the INN stem '-pixant' in the name indicates that Eliapixant is a purinoreceptor (P2X) antagonist.
Tandutinib
go.drugbank.com/drugs/DB05465InvestigationalTyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. … AML patients with FLT3 mutations experience earlier disease relapse and shorter survival rates compared to patients without these mutations.
Oxabolone cipionate
go.drugbank.com/drugs/DB13185ExperimentalIt is considered as a performance enhancing drug thus is prohibited from use in sports.
ATG-Fresenius S
go.drugbank.com/drugs/DB05320InvestigationalATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.
CM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066
Synonyms: BENZAMIDE, N-(5-(6-CHLORO-2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)-2-PYRAZINYL)-2-FLUORO-6-METHYL-, N-(5-(6-CHLORO-2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)PYRAZIN-2-YL)-2-FLUORO-6-METHYLBENZAMIDEBrolucizumab
go.drugbank.com/drugs/DB14864ApprovedInvestigational[L9089] Brolucizumab was granted FDA approval in October 2019.[L9089]